Lv4
450 积分 2021-05-14 加入
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
1个月前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Ribociclib-induced autoimmune-like hepatitis: a case report
8个月前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
8个月前
已完结
皖公网安备34019202002308
